Rachel Angers is currently the Associate Director at UCB, where they lead efforts in cellular and biomarker research related to neurodegenerative diseases. With a Ph.D. in Microbiology from the University of Kentucky and a Bachelor of Science from Colorado State University, they possess deep expertise in preclinical development and the implementation of biomarkers in clinical studies. Previously, they contributed to research at N30 Pharmaceuticals and Eli Lilly and Company, where they focused on neurobiology and cellular modeling of diseases such as Alzheimer's. Rachel’s extensive background includes training junior scientists and driving collaborative research initiatives throughout their career.
This person is not in the org chart
This person is not in any teams
This person is not in any offices